PFKP is a prospective prognostic, diagnostic, immunological and drug sensitivity predictor across pan-cancer

作者：Jian Ming Peng, Pingping Li, Yuan Li, Jichuan Quan, Yanwei Yao, Junfang Duan, Xuemei Liu, Hao Li, Dajiang Yuan, Xiaoru Wang · 发表于：Scientific Reports · 年份：2023 · DOI：10.1038/s41598-023-43982-2 · 被引用次数：49 · 研究领域：Cancer, Lipids, and Metabolism、Ferroptosis and cancer prognosis、Epigenetics and DNA Methylation

Phosphofructokinase, platelet (PFKP) is a rate-limiting enzyme of glycolysis that plays a decisive role in various human physio-pathological processes. PFKP has been reported to have multiple functions in different cancer types, including lung cancer and breast cancer. However, no systematic pancancer analysis of PFKP has been performed; this type of analysis could elucidate the clinical value of PFKP in terms of diagnosis, prognosis, drug sensitivity, and immunological correlation. Systematic bioinformation analysis of PFKP was performed based on several public datasets, including The Cancer Genome Atlas (TCGA), Cancer Cell Line Encyclopedia (CCLE), Genotype-Tissue Expression Project (GTEx), and Human Protein Atlas (HPA). Prospective carcinogenesis of PFKP across cancers was estimated by expression analysis, effect on patient prognosis, diagnosis significance evaluation, and immunity regulation estimation. Then, pancancer functional enrichment of PFKP was also assessed through its effect on the signaling score and gene expression profile. Finally, upstream expression regulation of PFKP was explored by promoter DNA methylation and transcription factor (TF) prediction. Our analysis revealed that high expression of PFKP was found in most cancer types. Additionally, a high level of PFKP displayed a significant correlation with poor prognosis in patients across cancers. The diagnostic value of PFKP was performed based on its positive correlation with programmed cell death-ligand ...